期刊
ANNALS OF SURGICAL ONCOLOGY
卷 24, 期 10, 页码 2876-2880出版社
SPRINGER
DOI: 10.1245/s10434-017-5961-9
关键词
-
资金
- Innocrin
- Pfizer/Medivation
- Astellas
A growing body of literature supports the conclusion that the androgen receptor (AR) plays an important role in breast cancer pathogenesis and may prove to be a relevant therapeutic target for patients with AR-driven breast cancer. This has been most apparent in the subset of patients with triple-negative breast cancer (TNBC), in whom approximately 50% of tumors may have androgen dependence. Recent phase 2 clinical trials of agents that antagonize AR or reduce androgen production have shown clinical benefit and efficacy to varying degrees. This review highlights three of these recent trials of AR(+) TNBC and acknowledge ongoing research in this exciting area.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据